The Top 5 Biosimilars Articles for the Week of April 15
The Center for Biosimilars® recaps the top news for the week of April 15, 2019.
Transcript
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of April 15.
Number 5: The Community Oncology Alliance (COA) has released a position statement about biosimilars, saying it will work with stakeholders to support the acceptance of these drugs.
Number 4: A pharmacy benfit manager says that the first year of its biosimilar management program has led to strong uptake of Inflectra.
Number 3: The Institute for Clinical and Economic Review will assess rheumatoid arthritis treatments, including biosimilar infliximab.
Number 2: A 2-part proposal argues that biosimilar competition is an economically inefficient way to achieve the goal of lower prices.
Number 1: Health Canada has approved Celltrion and Teva’s biosimilar rituximab, Truxima, for both oncology and rheumatology indications.
Finally, last week, our e-newsletter asked whether you think drug makers will attempt to differentiate their biosimilars through innovation.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
